Cargando…

Analysis of real-world data on growth hormone therapy adherence using a connected injection device

BACKGROUND: Poor adherence to long-term recombinant human growth hormone (r-hGH) treatment can lead to suboptimal clinical outcomes; consequently, supporting and monitoring adherence is a crucial part of patient management. We assessed adherence to r-hGH treatment in children with growth disorders o...

Descripción completa

Detalles Bibliográficos
Autores principales: Koledova, Ekaterina, Tornincasa, Vincenzo, van Dommelen, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389874/
https://www.ncbi.nlm.nih.gov/pubmed/32727461
http://dx.doi.org/10.1186/s12911-020-01183-1
_version_ 1783564425335144448
author Koledova, Ekaterina
Tornincasa, Vincenzo
van Dommelen, Paula
author_facet Koledova, Ekaterina
Tornincasa, Vincenzo
van Dommelen, Paula
author_sort Koledova, Ekaterina
collection PubMed
description BACKGROUND: Poor adherence to long-term recombinant human growth hormone (r-hGH) treatment can lead to suboptimal clinical outcomes; consequently, supporting and monitoring adherence is a crucial part of patient management. We assessed adherence to r-hGH treatment in children with growth disorders over 48 months using a connected monitoring device (easypod™), which automatically transmits adherence data via an online portal (easypod™ connect); both sit within an adherence decision support system (ADSS). We also investigated the effect of age and sex on adherence. METHODS: Data from children transmitting over 10 injections between January 2007 and February 2019 were analyzed. Adherence (mg injected/mg prescribed) was categorized as high (≥85%), intermediate (> 56–84%) or low (≤56%) and assessed at seven time points from the start of treatment up to 48 months. Adherence was investigated over time and stratified by puberty status and sex. Mean transmission rate in each adherence category (total number of transmissions/total number of children) at each time point was calculated as a proxy measure of engagement in disease and treatment management. Descriptive analyses were performed. RESULTS: Longitudinal records were available for 13,553 children. Overall, 71% (n = 9578) had high adherence, 22% (n = 2989) intermediate and 7% (n = 986) low. The proportion of children with high adherence decreased over time from 87% (n = 12,964) to 65% (n = 957) and was higher in pre-pubertal than pubertal children (girls: 80% [n = 1270] vs 70% [n = 4496]; boys 79% [n = 2573] vs 65% [n = 5214]). Children with high adherence had a higher mean number of transmissions (12.5 [SD 24.9]) than children with intermediate (7.2 [SD 15.3]) or low (3.5 [SD 5.7]) adherence. CONCLUSIONS: High adherence was seen in patients administering r-hGH using the connected device. Children with high adherence were most likely to regularly transmit data. Pubertal children showed lower adherence. We show the potential to develop an ADSS to analyze trends in real-world adherence data. This may prove useful to direct interventions to improve adherence while the ability to readily share data with healthcare professionals may itself improve adherence.
format Online
Article
Text
id pubmed-7389874
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73898742020-07-31 Analysis of real-world data on growth hormone therapy adherence using a connected injection device Koledova, Ekaterina Tornincasa, Vincenzo van Dommelen, Paula BMC Med Inform Decis Mak Research Article BACKGROUND: Poor adherence to long-term recombinant human growth hormone (r-hGH) treatment can lead to suboptimal clinical outcomes; consequently, supporting and monitoring adherence is a crucial part of patient management. We assessed adherence to r-hGH treatment in children with growth disorders over 48 months using a connected monitoring device (easypod™), which automatically transmits adherence data via an online portal (easypod™ connect); both sit within an adherence decision support system (ADSS). We also investigated the effect of age and sex on adherence. METHODS: Data from children transmitting over 10 injections between January 2007 and February 2019 were analyzed. Adherence (mg injected/mg prescribed) was categorized as high (≥85%), intermediate (> 56–84%) or low (≤56%) and assessed at seven time points from the start of treatment up to 48 months. Adherence was investigated over time and stratified by puberty status and sex. Mean transmission rate in each adherence category (total number of transmissions/total number of children) at each time point was calculated as a proxy measure of engagement in disease and treatment management. Descriptive analyses were performed. RESULTS: Longitudinal records were available for 13,553 children. Overall, 71% (n = 9578) had high adherence, 22% (n = 2989) intermediate and 7% (n = 986) low. The proportion of children with high adherence decreased over time from 87% (n = 12,964) to 65% (n = 957) and was higher in pre-pubertal than pubertal children (girls: 80% [n = 1270] vs 70% [n = 4496]; boys 79% [n = 2573] vs 65% [n = 5214]). Children with high adherence had a higher mean number of transmissions (12.5 [SD 24.9]) than children with intermediate (7.2 [SD 15.3]) or low (3.5 [SD 5.7]) adherence. CONCLUSIONS: High adherence was seen in patients administering r-hGH using the connected device. Children with high adherence were most likely to regularly transmit data. Pubertal children showed lower adherence. We show the potential to develop an ADSS to analyze trends in real-world adherence data. This may prove useful to direct interventions to improve adherence while the ability to readily share data with healthcare professionals may itself improve adherence. BioMed Central 2020-07-29 /pmc/articles/PMC7389874/ /pubmed/32727461 http://dx.doi.org/10.1186/s12911-020-01183-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Koledova, Ekaterina
Tornincasa, Vincenzo
van Dommelen, Paula
Analysis of real-world data on growth hormone therapy adherence using a connected injection device
title Analysis of real-world data on growth hormone therapy adherence using a connected injection device
title_full Analysis of real-world data on growth hormone therapy adherence using a connected injection device
title_fullStr Analysis of real-world data on growth hormone therapy adherence using a connected injection device
title_full_unstemmed Analysis of real-world data on growth hormone therapy adherence using a connected injection device
title_short Analysis of real-world data on growth hormone therapy adherence using a connected injection device
title_sort analysis of real-world data on growth hormone therapy adherence using a connected injection device
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389874/
https://www.ncbi.nlm.nih.gov/pubmed/32727461
http://dx.doi.org/10.1186/s12911-020-01183-1
work_keys_str_mv AT koledovaekaterina analysisofrealworlddataongrowthhormonetherapyadherenceusingaconnectedinjectiondevice
AT tornincasavincenzo analysisofrealworlddataongrowthhormonetherapyadherenceusingaconnectedinjectiondevice
AT vandommelenpaula analysisofrealworlddataongrowthhormonetherapyadherenceusingaconnectedinjectiondevice